Proteonano Imports Face Possible U.S. Ban

A federal trade panel's staff backs blocking Nanomics' proteomics products, with a final decision expected by year's end.

Updated on Nov. 5, 2026 in Biotech

Bold flat-color editorial illustration of stacked steel shipping containers beside a crane arm on an empty port quay in navy and cream.
The U.S. International Trade Commission's staff recommended blocking imports of Nanomics' Proteonano products after the company defaulted in a patent case brought by Seer. AI Illustration. Upload story photo >

The U.S. International Trade Commission's investigative staff has recommended full exclusion and cease-and-desist orders against Nanomics Biotechnology after the company stopped defending itself in a patent case brought by Seer. The recommendation is a staff step, not a final ruling; the Commission is expected to reach a final determination by year's end.

Why it matters

Because Nanomics defaulted, the allegations in Seer's complaint are presumed true for Nanomics' Proteonano products, which shifts the ITC's attention straight to remedies. The case sits alongside a separate federal lawsuit by Seer and Brigham and Women's Hospital and a March Patent Trial and Appeal Board ruling upholding key claims of a Seer nanoparticle protein enrichment patent.

The evidence is a staff recommendation from the ITC's Office of Unfair Import Investigations, which proposed granting every remedy Seer requested against Nanomics' Proteonano products. No third-party submissions opposed the requested orders, but the Commission has not yet acted, and the final outcome depends on its determination expected by year's end.

The players

Seer

A Redwood City, California proteomics company whose nanoparticle protein enrichment patent is at the center of the ITC and federal cases.

Nanomics Biotechnology

A company whose Proteonano products are the subject of the ITC investigation, which it stopped defending in September.

Brigham and Women's Hospital

A Boston hospital and co-complainant with Seer in both the ITC proceeding and the related federal patent lawsuit.

U.S. International Trade Commission

The federal agency that investigates imported goods for patent infringement and can issue exclusion and cease-and-desist orders.

The details

The ITC is a federal body that can block imports found to infringe U.S. intellectual property, using exclusion orders that stop infringing goods at the border and cease-and-desist orders that bar sales. Because Nanomics chose not to participate, ITC rules treat the allegations in Seer's complaint as presumed true for Nanomics' products, so staff moved directly to recommending remedies. Seer makes proteomics tools, which study the full set of proteins in a biological sample, and its patent covers particle-based enrichment, a method that uses nanoparticles to capture proteins so they can be measured.

Timeline

  1. May 2026: Seer asked the ITC to investigate Nanomics' Proteonano products.

  2. September 2026: Nanomics notified the ITC that it would stop defending itself.

  3. October 30, 2026: ITC staff recommended granting the full remedies Seer requested.

  4. End of 2026: The Commission is expected to reach a final determination.

The Tech Race

The ITC route is one of several parallel fronts in the proteomics patent fight, alongside the federal lawsuit and the March Patent Trial and Appeal Board ruling upholding Seer's claims. A June European Patent Office decision maintaining a related particle-based enrichment patent suggests Seer's position is being tested across multiple jurisdictions at once.

If the Commission adopts the staff recommendation, Proteonano products imported into the United States could be excluded at the border and sales barred, which would affect labs that buy these proteomics tools. Labs should watch the Commission's final determination before relying on Nanomics products, since the outcome is not yet settled.

The takeaway

Watch the Commission's final determination expected by year's end, which will show whether exclusion orders are issued against Nanomics. A ruling in Seer's favor would strengthen its patent position across the ITC, federal court, and the European Patent Office.

What happens next

The Commission is expected to reach its final determination by the end of 2026, which will decide whether the exclusion and cease-and-desist orders take effect.

Further reading

For more on the research tools at the center of this dispute, explore Biotech coverage.

Source note: This article includes information reported by The Manila times.